Advertisement

Oncolytic Measles Virus Retargeting by Ligand Display

Protocol
First Online:
Part of the Methods in Molecular Biology book series (MIMB, volume 797)

Abstract

Despite significant advances in recent years, treatment of metastatic malignancies remains a significant challenge. There is an urgent need for development of novel therapeutic approaches. Virotherapy approaches have considerable potential, and among them measles virus (MV) vaccine strains have emerged as a promising oncolytic platform. Retargeted MV strains deriving from the Edmonston vaccine lineage (MV-Edm) have shown comparable antitumor efficacy to unmodified strains against receptor expressing tumor cells with improved therapeutic index. Here, we describe the construction, rescue, amplification, and titration of fully retargeted MV-Edm derivatives displaying tumor specific receptor binding ligands on the viral surface in combination with H protein CD46 and SLAM entry ablating mutations.

Key words

Oncolytic measles virus Measles retargeting Virotherapy Measles engineering 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Peng, K. W., TenEyck, C. J., Galanis, E., Kalli, K. R., Hartmann, L. C., and Russell, S. J. (2002) Intraperitoneal therapy of ovarian cancer using an engineered measles virus, Cancer research 62, 4656–4662.PubMedGoogle Scholar
  2. 2.
    Hasegawa, K., Pham, L., O’Connor, M. K., Federspiel, M. J., Russell, S. J., and Peng, K. W. (2006) Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter, Clin Cancer Res 12, 1868–1875.CrossRefGoogle Scholar
  3. 3.
    Phuong, L. K., Allen, C., Peng, K. W., Giannini, C., Greiner, S., TenEyck, C. J., Mishra, P. K., Macura, S. I., Russell, S. J., and Galanis, E. C. (2003) Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme, Cancer research 63, 2462–2469.PubMedGoogle Scholar
  4. 4.
    Peng, K. W., Ahmann, G. J., Pham, L., Greipp, P. R., Cattaneo, R., and Russell, S. J. (2001) Systemic therapy of myeloma xenografts by an attenuated measles virus, Blood 98, 2002–2007.CrossRefGoogle Scholar
  5. 5.
    Dingli, D., Peng, K. W., Harvey, M. E., Greipp, P. R., O’Connor, M. K., Cattaneo, R., Morris, J. C., and Russell, S. J. (2004) Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter, Blood 103, 1641–1646.CrossRefGoogle Scholar
  6. 6.
    Grote, D., Russell, S. J., Cornu, T. I., Cattaneo, R., Vile, R., Poland, G. A., and Fielding, A. K. (2001) Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice, Blood 97, 3746–3754.CrossRefGoogle Scholar
  7. 7.
    McDonald, C. J., Erlichman, C., Ingle, J. N., Rosales, G. A., Allen, C., Greiner, S. M., Harvey, M. E., Zollman, P. J., Russell, S. J., and Galanis, E. (2006) A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer, Breast cancer research and treatment 99, 177–184.CrossRefGoogle Scholar
  8. 8.
    Iankov, I. D., Msaouel, P., Allen, C., Federspiel, M. J., Bulur, P. A., Dietz, A. B., Gastineau, D., Ikeda, Y., Ingle, J. N., Russell, S. J., and Galanis, E. (2009) Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model, Breast cancer research and treatment 2010 Aug;122(3), 745–54.CrossRefGoogle Scholar
  9. 9.
    Msaouel, P., Iankov, I. D., Allen, C., Morris, J. C., von Messling, V., Cattaneo, R., Koutsilieris, M., Russell, S. J., and Galanis, E. (2009) Engineered measles virus as a novel oncolytic therapy against prostate cancer, The Prostate 69, 82–91.CrossRefGoogle Scholar
  10. 10.
    Msaouel, P., Iankov, I. D., Allen, C., Aderca, I., Federspiel, M. J., Tindall, D. J., Morris, J. C., Koutsilieris, M., Russell, S. J., and Galanis, E. (2009) Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter, Mol Ther 17, 2041–2048.CrossRefGoogle Scholar
  11. 11.
    Blechacz, B., Splinter, P. L., Greiner, S., Myers, R., Peng, K. W., Federspiel, M. J., Russell, S. J., and LaRusso, N. F. (2006) Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma, Hepatology (Baltimore, Md) 44, 1465–1477.CrossRefGoogle Scholar
  12. 12.
    Dorig, R. E., Marcil, A., Chopra, A., and Richardson, C. D. (1993) The human CD46 molecule is a receptor for measles virus (Edmonston strain), Cell 75, 295–305.CrossRefGoogle Scholar
  13. 13.
    Naniche, D., Varior-Krishnan, G., Cervoni, F., Wild, T. F., Rossi, B., Rabourdin-Combe, C., and Gerlier, D. (1993) Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus, Journal of virology 67, 6025–6032.CrossRefGoogle Scholar
  14. 14.
    Tatsuo, H., Ono, N., Tanaka, K., and Yanagi, Y. (2000) SLAM (CDw150) is a cellular receptor for measles virus, Nature 406, 893–897.CrossRefGoogle Scholar
  15. 15.
    Hahm, B., Arbour, N., Naniche, D., Homann, D., Manchester, M., and Oldstone, M. B. (2003) Measles virus infects and suppresses proliferation of T lymphocytes from transgenic mice bearing human signaling lymphocytic activation molecule, Journal of virology 77, 3505–3515.CrossRefGoogle Scholar
  16. 16.
    Schneider-Schaulies, S., Bieback, K., Avota, E., Klagge, I., and ter Meulen, V. (2002) Regulation of gene expression in lymphocytes and antigen-presenting cells by measles virus: consequences for immunomodulation, Journal of molecular medicine (Berlin, Germany) 80, 73–85.CrossRefGoogle Scholar
  17. 17.
    Yanagi, Y., Takeda, M., and Ohno, S. (2006) Measles virus: cellular receptors, tropism and pathogenesis, The Journal of general virology 87, 2767–2779.CrossRefGoogle Scholar
  18. 18.
    Nussbaum, O., Broder, C. C., Moss, B., Stern, L. B., Rozenblatt, S., and Berger, E. A. (1995) Functional and structural interactions between measles virus hemagglutinin and CD46, Journal of virology 69, 3341–3349.CrossRefGoogle Scholar
  19. 19.
    Allen, C., Paraskevakou, G., Iankov, I., Giannini, C., Schroeder, M., Sarkaria, J., Schroeder, M., Puri, R. K., Russell, S. J., and Galanis, E. (2008) Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity, Mol Ther 16, 1556–1564.CrossRefGoogle Scholar
  20. 20.
    Nakamura, T., Peng, K. W., Harvey, M., Greiner, S., Lorimer, I. A., James, C. D., and Russell, S. J. (2005) Rescue and propagation of fully retargeted oncolytic measles viruses, Nature biotechnology 23, 209–214.CrossRefGoogle Scholar
  21. 21.
    Paraskevakou, G., Allen, C., Nakamura, T., Zollman, P., James, C. D., Peng, K. W., Schroeder, M., Russell, S. J., and Galanis, E. (2007) Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas, Mol Ther 15, 677–686.CrossRefGoogle Scholar
  22. 22.
    Allen, C., Vongpunsawad, S., Nakamura, T., James, C. D., Schroeder, M., Cattaneo, R., Giannini, C., Krempski, J., Peng, K. W., Goble, J. M., Uhm, J. H., Russell, S. J., and Galanis, E. (2006) Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity, Cancer research 66, 11840–11850.CrossRefGoogle Scholar
  23. 23.
    Hasegawa, K., Nakamura, T., Harvey, M., Ikeda, Y., Oberg, A., Figini, M., Canevari, S., Hartmann, L. C., and Peng, K. W. (2006) The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer, Clin Cancer Res 12, 6170–6178.CrossRefGoogle Scholar
  24. 24.
    Jing, Y., Tong, C., Zhang, J., Nakamura, T., Iankov, I., Russell, S. J., and Merchan, J. R. (2009) Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor, Cancer research 69, 1459–1468.CrossRefGoogle Scholar
  25. 25.
    Hummel, H. D., Kuntz, G., Russell, S. J., Nakamura, T., Greiner, A., Einsele, H., and Topp, M. S. (2009) Genetically engineered attenuated measles virus specifically infects and kills primary multiple myeloma cells, The Journal of general virology 90, 693–701.CrossRefGoogle Scholar
  26. 26.
    Hasegawa, K., Hu, C., Nakamura, T., Marks, J. D., Russell, S. J., and Peng, K. W. (2007) Affinity thresholds for membrane fusion triggering by viral glycoproteins, Journal of virology 81, 13149–13157.CrossRefGoogle Scholar
  27. 27.
    Ungerechts, G., Springfeld, C., Frenzke, M. E., Lampe, J., Johnston, P. B., Parker, W. B., Sorscher, E. J., and Cattaneo, R. (2007) Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine, Cancer research 67, 10939–10947.CrossRefGoogle Scholar
  28. 28.
    Hallak, L. K., Merchan, J. R., Storgard, C. M., Loftus, J. C., and Russell, S. J. (2005) Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression, Cancer research 65, 5292–5300.CrossRefGoogle Scholar
  29. 29.
    Springfeld, C., von Messling, V., Frenzke, M., Ungerechts, G., Buchholz, C. J., and Cattaneo, R. (2006) Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases, Cancer research 66, 7694–7700.CrossRefGoogle Scholar
  30. 30.
    Msaouel, P., Dispenzieri, A., and Galanis, E. (2009) Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview, Current opinion in molecular therapeutics 11, 43–53.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Vongpunsawad, S., Oezgun, N., Braun, W., and Cattaneo, R. (2004) Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model, Journal of virology 78, 302–313.CrossRefGoogle Scholar
  32. 32.
    Nakamura, T., Peng, K. W., Vongpunsawad, S., Harvey, M., Mizuguchi, H., Hayakawa, T., Cattaneo, R., and Russell, S. J. (2004) Antibody-targeted cell fusion, Nature biotechnology 22, 331–336.CrossRefGoogle Scholar
  33. 33.
    Radecke, F., Spielhofer, P., Schneider, H., Kaelin, K., Huber, M., Dotsch, C., Christiansen, G., and Billeter, M. A. (1995) Rescue of measles viruses from cloned DNA, The EMBO journal 14, 5773–5784.CrossRefGoogle Scholar
  34. 34.
    Hadac, E. M., Peng, K. W., Nakamura, T., and Russell, S. J. (2004) Reengineering paramyxovirus tropism, Virology 329, 217–225.CrossRefGoogle Scholar
  35. 35.
    Douglas, J. T., Miller, C. R., Kim, M., Dmitriev, I., Mikheeva, G., Krasnykh, V., and Curiel, D. T. (1999) A system for the propagation of adenoviral vectors with genetically modified receptor specificities, Nature biotechnology 17, 470–475.CrossRefGoogle Scholar
  36. 36.
    Kolakofsky, D., Pelet, T., Garcin, D., Hausmann, S., Curran, J., and Roux, L. (1998) Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited, Journal of virology 72, 891–899.CrossRefGoogle Scholar
  37. 37.
    Peng, K. W., Donovan, K. A., Schneider, U., Cattaneo, R., Lust, J., and Russell, S. J. (2003) Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker, Blood 101, 2557–2562.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Mayo ClinicRochesterUSA
  2. 2.Department of Molecular MedicineMayo ClinicRochesterUSA

Personalised recommendations

Cite protocol

Buy options